Aim: The primary objective of this consensus document is to develop evidence-based consensus recommendations on the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) for contraception in the Indian setting. Background: The unintended pregnancy rate in India is among the highest in the world. Current contraceptive options for women in India include combined or progesterone-only contraceptive pills, vaginal ring, depot medroxyprogesterone acetate, copper intrauterine devices, LNG-IUS, and implants. However, currently, there are no India-specific guidelines/recommendations on the use of LNG-IUS in women. Therefore, an expert panel meeting was convened to arrive at practical recommendations for clinicians on the appropriate use of LNG-IUS. Review results: The panel comprising 15 obstetrics and gynecology experts from India discussed appropriate patient profiles for LNG-IUS and available evidence for the general population and women with comorbidities. The panel thoroughly reviewed the existing literature on contraception and put forth definitive recommendations to be followed on the use of LNG-IUS in the Indian setting. Consensus-based clinical recommendations were developed to serve as a reference for clinicians, regarding the use of LNG-IUS in the general population and women with comorbidities. Conclusion: The use of the LNG-IUS in selected population can ensure contraception and also enhance treatment outcomes. The consensus recommendations given in this document can guide clinicians toward the same in Indian settings. Clinical significance: The LNG-IUS, while being effective for contraception, offers several advantages in terms of reversibility, reduced pelvic infections, etc. Clinicians should carefully select the specific patient profiles/subgroups who would benefit from the use of LNG-IUS.
The new LNG-releasing IUS: a new opportunity to reduce the burden of unintended pregnancy. Eur J Obstet Gynecol Reprod Biol 2015;190:58–64. DOI: 10.1016/j.ejogrb.2015.04.016.
The incidence of abortion and unintended pregnancy in India, 2015. Lancet Glob Heal 2018;6(1):e111–e120. DOI: 10.1016/S2214-109X(17)30453-9.
A need for overhaul of policy on contraception and abortion in India. Lancet Glob Health 2018;6(1):e16–e17. DOI: 10.1016/S2214-109X(17)30473-4.
Family planning in India: The way forward. Indian J Med Res. 2018;148(Suppl 1):S1–S9.
Ministry of Health and Family Welfare. Government of India. Contraceptive Updates. Reference Manual for Doctors. Available at: https://india.unfpa.org/sites/default/files/pubpdf/contraceptiveReferenceManualFinal7Nov2005.pdf Accessed on: 30 May 2019.
One-year quality of life measured with SEC-QoL in levonorgestrel 52 mg IUS users. Contraception 2016;93(4):367–371. DOI: 10.1016/j.contraception.2015.12.014.
WHO Model List of Essential Medicines. 20th List. (2017). Available at: https://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf?ua=1. Accessed on: 30 May 2019.
EML 2015 – application for the levonorgestrel-releasing intrauterine system (LNG-IUS). Available from: https://www.who.int/selection_medicines/committees/expert/20/applications/LNG_IUS.pdf?ua=1. Accessed on: 30 May 2019.
The levonorgestrel-releasing intrauterine system: safety, efficacy, and patient acceptability. Ther Clin Risk Manag 2009;5(3):561–574.
GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64(4):383–394. DOI: 10.1016/j.jclinepi.2010.04.026.
Levonorgestrel-releasing intra-uterine systems as female contraceptives. Expert Opin Pharmacother 2018;19(7):677–686. DOI: 10.1080/14656566.2018.1462337.
Progestogen-releasing intrauterine systems versus other forms of reversible contraceptives for contraception. Cochrane Database Syst Rev 2004(3):1–73.
Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004;190(1):50–54. DOI: 10.1016/j.ajog.2003.07.021.
Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. Contraception 2015;92(1):10–16. DOI: 10.1016/j.contraception.2015.04.006.
Five-year contraceptive efficacy and safety of a levonorgestrel 52-mg intrauterine system. Obstet Gynecol 2019;133(1):63–70. DOI: 10.1097/AOG.0000000000003034.
Pregnancy outcomes associated with extended use of the 52-mg 20 μg/day levonorgestrel-releasing intrauterine system beyond 60 months: a chart review of 776 women in Brazil. Contraception 2018;97(3):205–209. DOI: 10.1016/j.contraception.2017.10.007.
Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review. Am J Obstet Gynecol 2017;216(6):590.e1–590.e8. DOI: 10.1016/j.ajog.2017.02.003.
Why perimenopausal women should consider to use a levonorgestrel intrauterine system. Gynecol Endocrinol 2016;32(8):659–661. DOI: 10.3109/09513590.2016.1153056.
The levonorgestrel intrauterine system for use in peri- and postmenopausal women. Contraception 2007;75(6 Suppl.):S155–S160. DOI: 10.1016/j.contraception.2007.01.010.
The LNG-IUS study on adenomyosis: A 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis. Contraception 2009;79(3):189–193. DOI: 10.1016/j.contraception.2008.11.004.
Safety and efficacy of the levonorgestrel-releasing intrauterine system: recent insights. Exp Rev Obstet Gynecol 2014. 235–247.
The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding. A benefit-risk review. Drugs 2012;72(2):193–215. DOI: 10.2165/11598960-000000000-00000.
Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis. Contraception 2012;86(5):458–463. DOI: 10.1016/j.contraception.2012.04.001.
Hemoglobin and serum ferritin levels in women using copper-releasing or levonorgestrel-releasing intrauterine devices: a systematic review. Contraception 2013;87(4):486–496. DOI: 10.1016/j.contraception.2012.09.025.
Levonorgestrel-releasing intrauterine system for women with polycystic ovary syndrome. Reprod Sci 2016;23(7):877–884. DOI: 10.1177/1933719115623648.
Contraception in women with cardiac disease. Women's Heal 2007;3(6):711–717. DOI: 10.2217/17455057.3.6.711.
Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366(24):2257–2266. DOI: 10.1056/NEJMoa1111840.
Efficacy and safety of long-acting reversible contraception in women with cardiovascular conditions. Am J Cardiol 2016;117(2):302–304. DOI: 10.1016/j.amjcard.2015.10.026.
Safety and efficacy of a 52-mg levonorgestrel-releasing intrauterine system in women with cardiovascular disease. J Obstet Gynaecol Res 2019;45(2):382–388. DOI: 10.1111/jog.13828.
Effect of a levonorgestrel intrauterine system on women with type 1 diabetes: a randomized trial. Obstet Gynecol 2005;105(4):811–815. DOI: 10.1097/01.AOG.0000156301.11939.56.
Contraception counseling in SLE—an often forgotten duty? Nat Rev Rheumatol 2011;7(6):315–316. DOI: 10.1038/nrrheum.2011.54.
Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome: users of the 52-mg levonorgestrel-releasing intrauterine system. Arch Gynecol Obstet 2019;299(6):1597–1605. DOI: 10.1007/s00404-019-05131-x.
Low-dielectric-constant polyimide aerogel composite films with low water uptake. Polym J 2016;48(7):829–834. DOI: 10.1038/pj.2016.37.
LNG-IUS 12: A 19.5 levonorgestrel-releasing intrauterine system for prevention of pregnancy for up to five years. Expert Opin Drug Deliv 2017;14(9):1131–1140. DOI: 10.1080/17425247.2017.1353972.
Clarification of the role of the Jaydess(Skyla) LNG-IUS 13.5mg and Kyleena LNG-IUS 19.5mg as intrauterine contraceptive systems. Expert Rev Med Devices 2017;14(8):593–599. DOI: 10.1080/17434440.2017.1350169.